# Envista Holdings Corp: financial statements, quarterly

NVST · NYSE · CIK 1757073 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nvst.md) · [Financials](/companies/nvst/financials.md) · [Filings](/companies/nvst/filings.md) · [Insiders](/companies/nvst/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nvst/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-29) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-28) | Q2 FY2025 (2025-06-27) | Q3 FY2025 (2025-09-26) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [631](/filings/0001757073-24-000078.md) | [646 d](/filings/0001757073-26-000011.md) | [624](/filings/0001757073-25-000028.md) | [633](/filings/0001757073-25-000044.md) | [601](/filings/0001757073-25-000058.md) | [653 d](/filings/0001757073-26-000011.md) | [617](/filings/0001757073-26-000042.md) | [682](/filings/0001757073-26-000066.md) | [670](/filings/0001757073-25-000058.md) | [751 d](/filings/0001757073-26-000011.md) | [706](/filings/0001757073-26-000042.md) | [731](/filings/0001757073-26-000066.md) |
| Cost of revenue | $m | [268](/filings/0001757073-24-000078.md) | [310 d](/filings/0001757073-26-000011.md) | [267](/filings/0001757073-25-000028.md) | [307](/filings/0001757073-25-000044.md) | [284](/filings/0001757073-25-000058.md) | [280 d](/filings/0001757073-26-000011.md) | [281](/filings/0001757073-26-000042.md) | [312](/filings/0001757073-26-000066.md) | [300](/filings/0001757073-25-000058.md) | [340 d](/filings/0001757073-26-000011.md) | [315](/filings/0001757073-26-000042.md) | [324](/filings/0001757073-26-000066.md) |
| Gross profit | $m | [363](/filings/0001757073-24-000078.md) | [336 d](/filings/0001757073-26-000011.md) | [356](/filings/0001757073-25-000028.md) | [327](/filings/0001757073-25-000044.md) | [317](/filings/0001757073-25-000058.md) | [373 d](/filings/0001757073-26-000011.md) | [336](/filings/0001757073-26-000042.md) | [370](/filings/0001757073-26-000066.md) | [370](/filings/0001757073-25-000058.md) | [411 d](/filings/0001757073-26-000011.md) | [390](/filings/0001757073-26-000042.md) | [407](/filings/0001757073-26-000066.md) |
| Research and development | $m | [22.3](/filings/0001757073-24-000078.md) | [20.2 d](/filings/0001757073-26-000011.md) | [23.3](/filings/0001757073-25-000028.md) | [23.6](/filings/0001757073-25-000044.md) | [25.5](/filings/0001757073-25-000058.md) | [26.7 d](/filings/0001757073-26-000011.md) | [25.3](/filings/0001757073-26-000042.md) | [28.3](/filings/0001757073-26-000066.md) | [28.3](/filings/0001757073-25-000058.md) | [32.1 d](/filings/0001757073-26-000011.md) | [30.0](/filings/0001757073-26-000042.md) | [30.4](/filings/0001757073-26-000066.md) |
| Selling, general and administrative | $m | [258](/filings/0001757073-24-000078.md) | [260 d](/filings/0001757073-26-000011.md) | [285](/filings/0001757073-25-000028.md) | [303](/filings/0001757073-25-000044.md) | [271](/filings/0001757073-25-000058.md) | [300 d](/filings/0001757073-26-000011.md) | [272](/filings/0001757073-26-000042.md) | [295](/filings/0001757073-26-000066.md) | [284](/filings/0001757073-25-000058.md) | [305 d](/filings/0001757073-26-000011.md) | [298](/filings/0001757073-26-000042.md) | [296](/filings/0001757073-26-000066.md) |
| Operating income | $m | [83.3](/filings/0001757073-24-000078.md) | [(203) d](/filings/0001757073-26-000011.md) | [48.1](/filings/0001757073-25-000028.md) | [(1,153)](/filings/0001757073-25-000044.md) | [20.9](/filings/0001757073-25-000058.md) | [46.1 d](/filings/0001757073-26-000011.md) | [39.0](/filings/0001757073-26-000042.md) | [46.3](/filings/0001757073-26-000066.md) | [57.5](/filings/0001757073-25-000058.md) | [73.3 d](/filings/0001757073-26-000011.md) | [62.5](/filings/0001757073-26-000042.md) | [80.3](/filings/0001757073-26-000066.md) |
| Interest expense | $m | [15.4](/filings/0001757073-23-000071.md) | [13.9 d](/filings/0001757073-24-000019.md) | [12.9](/filings/0001757073-24-000039.md) | [11.7](/filings/0001757073-24-000066.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [14.3](/filings/0001757073-24-000078.md) | [2.4 d](/filings/0001757073-26-000011.md) | [11.7](/filings/0001757073-25-000028.md) | [(14.5)](/filings/0001757073-25-000044.md) | [1.4](/filings/0001757073-25-000058.md) | [35.3 d](/filings/0001757073-26-000011.md) | [11.0](/filings/0001757073-26-000042.md) | [14.3](/filings/0001757073-26-000066.md) | [80.2](/filings/0001757073-25-000058.md) | [24.7 d](/filings/0001757073-26-000011.md) | [13.5](/filings/0001757073-26-000042.md) | [20.7](/filings/0001757073-26-000066.md) |
| Net income | $m | [21.5](/filings/0001757073-24-000078.md) | [(217) d](/filings/0001757073-26-000011.md) | [23.6](/filings/0001757073-25-000058.md) | [(1,152)](/filings/0001757073-25-000058.md) | [8.2](/filings/0001757073-25-000058.md) | [1.2 d](/filings/0001757073-26-000011.md) | [18.0](/filings/0001757073-26-000066.md) | [26.4](/filings/0001757073-26-000066.md) | [(30.3)](/filings/0001757073-25-000058.md) | [32.9 d](/filings/0001757073-26-000011.md) | [38.7](/filings/0001757073-26-000066.md) | [53.7](/filings/0001757073-26-000066.md) |
| Diluted EPS | $ per share | [0.12](/filings/0001757073-24-000078.md) | not reported | [0.14](/filings/0001757073-25-000028.md) | [(6.69)](/filings/0001757073-25-000044.md) | [0.05](/filings/0001757073-25-000058.md) | not reported | [0.10](/filings/0001757073-26-000042.md) | [0.16](/filings/0001757073-26-000066.md) | [(0.18)](/filings/0001757073-25-000058.md) | not reported | [0.23](/filings/0001757073-26-000042.md) | [0.33](/filings/0001757073-26-000066.md) |
| Basic EPS | $ per share | [0.13](/filings/0001757073-24-000078.md) | not reported | [0.14](/filings/0001757073-25-000028.md) | [(6.69)](/filings/0001757073-25-000044.md) | [0.05](/filings/0001757073-25-000058.md) | not reported | [0.10](/filings/0001757073-26-000042.md) | [0.16](/filings/0001757073-26-000066.md) | [(0.18)](/filings/0001757073-25-000058.md) | not reported | [0.24](/filings/0001757073-26-000042.md) | [0.33](/filings/0001757073-26-000066.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-29) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-28) | Q2 FY2025 (2025-06-27) | Q3 FY2025 (2025-09-26) | FY2025 (2025-12-31) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [824](/filings/0001757073-23-000071.md) | [940](/filings/0001757073-25-000007.md) | [949](/filings/0001757073-24-000039.md) | [1,036](/filings/0001757073-24-000066.md) | [991](/filings/0001757073-24-000078.md) | [1,069](/filings/0001757073-26-000011.md) | [1,077](/filings/0001757073-25-000028.md) | [1,111](/filings/0001757073-25-000044.md) | [1,134](/filings/0001757073-25-000058.md) | [1,212](/filings/0001757073-26-000066.md) | [1,083](/filings/0001757073-26-000042.md) | [1,126](/filings/0001757073-26-000066.md) |
| Current assets | $m | [1,641](/filings/0001757073-23-000071.md) | [1,744](/filings/0001757073-25-000007.md) | [1,772](/filings/0001757073-24-000039.md) | [1,822](/filings/0001757073-24-000066.md) | [1,797](/filings/0001757073-24-000078.md) | [1,788](/filings/0001757073-26-000011.md) | [1,850](/filings/0001757073-25-000028.md) | [1,935](/filings/0001757073-25-000044.md) | [1,948](/filings/0001757073-25-000058.md) | [2,027](/filings/0001757073-26-000066.md) | [1,919](/filings/0001757073-26-000042.md) | [1,958](/filings/0001757073-26-000066.md) |
| Total assets | $m | [6,684](/filings/0001757073-23-000071.md) | [6,605](/filings/0001757073-25-000007.md) | [6,556](/filings/0001757073-24-000039.md) | [5,438](/filings/0001757073-24-000066.md) | [5,511](/filings/0001757073-24-000078.md) | [5,351](/filings/0001757073-26-000011.md) | [5,466](/filings/0001757073-25-000028.md) | [5,664](/filings/0001757073-25-000044.md) | [5,643](/filings/0001757073-25-000058.md) | [5,679](/filings/0001757073-26-000066.md) | [5,578](/filings/0001757073-26-000042.md) | [5,597](/filings/0001757073-26-000066.md) |
| Current liabilities | $m | [747](/filings/0001757073-23-000071.md) | [781](/filings/0001757073-25-000007.md) | [781](/filings/0001757073-24-000039.md) | [821](/filings/0001757073-24-000066.md) | [866](/filings/0001757073-24-000078.md) | [879](/filings/0001757073-26-000011.md) | [873](/filings/0001757073-25-000028.md) | [794](/filings/0001757073-25-000044.md) | [822](/filings/0001757073-25-000058.md) | [853](/filings/0001757073-26-000066.md) | [787](/filings/0001757073-26-000042.md) | [807](/filings/0001757073-26-000066.md) |
| Long-term debt | $m | [1,381](/filings/0001757073-23-000071.md) | [1,398](/filings/0001757073-25-000007.md) | [1,391](/filings/0001757073-24-000039.md) | [1,389](/filings/0001757073-24-000066.md) | [1,306](/filings/0001757073-24-000078.md) | [1,278](/filings/0001757073-26-000011.md) | [1,296](/filings/0001757073-25-000028.md) | [1,445](/filings/0001757073-25-000044.md) | [1,445](/filings/0001757073-25-000058.md) | [1,448](/filings/0001757073-26-000066.md) | [1,439](/filings/0001757073-26-000042.md) | [1,436](/filings/0001757073-26-000066.md) |
| Current portion of debt | $m | [115](/filings/0001757073-23-000071.md) | [115](/filings/0001757073-25-000007.md) | [116](/filings/0001757073-24-000039.md) | [116](/filings/0001757073-24-000066.md) | [116](/filings/0001757073-24-000078.md) | [116](/filings/0001757073-26-000011.md) | [116](/filings/0001757073-25-000028.md) | [0.0](/filings/0001757073-25-000044.md) | [0.0](/filings/0001757073-25-000058.md) | [0.0](/filings/0001757073-26-000011.md) | not reported | not reported |
| Short-term borrowings | $m | [115](/filings/0001757073-23-000071.md) | [115](/filings/0001757073-25-000007.md) | [116](/filings/0001757073-24-000039.md) | [116](/filings/0001757073-24-000066.md) | [116](/filings/0001757073-24-000078.md) | [116](/filings/0001757073-26-000011.md) | [116](/filings/0001757073-25-000028.md) | [0.0](/filings/0001757073-25-000044.md) | [0.0](/filings/0001757073-25-000058.md) | [0.0](/filings/0001757073-26-000011.md) | not reported | not reported |
| Shareholders' equity | $m | [4,293](/filings/0001757073-24-000078.md) | [4,174](/filings/0001757073-26-000011.md) | [4,140](/filings/0001757073-25-000058.md) | [2,977](/filings/0001757073-25-000058.md) | [3,073](/filings/0001757073-25-000058.md) | [2,935](/filings/0001757073-26-000066.md) | [3,036](/filings/0001757073-26-000066.md) | [3,139](/filings/0001757073-26-000066.md) | [3,088](/filings/0001757073-25-000058.md) | [3,106](/filings/0001757073-26-000066.md) | [3,080](/filings/0001757073-26-000066.md) | [3,076](/filings/0001757073-26-000066.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:DebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-29) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-28) | Q2 FY2025 (2025-06-27) | Q3 FY2025 (2025-09-26) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [95.5 d](/filings/0001757073-24-000078.md) | [102 d](/filings/0001757073-26-000011.md) | [40.3](/filings/0001757073-25-000028.md) | [93.1 d](/filings/0001757073-25-000044.md) | [70.7 d](/filings/0001757073-25-000058.md) | [132 d](/filings/0001757073-26-000011.md) | [0.3](/filings/0001757073-26-000042.md) | [88.7 d](/filings/0001757073-26-000066.md) | [78.7 d](/filings/0001757073-25-000058.md) | [108 d](/filings/0001757073-26-000011.md) | [(3.3)](/filings/0001757073-26-000042.md) | [119 d](/filings/0001757073-26-000066.md) |
| Capital expenditure | $m | [18.4 d](/filings/0001757073-24-000078.md) | [8.2 d](/filings/0001757073-26-000011.md) | [11.0](/filings/0001757073-25-000028.md) | [6.8 d](/filings/0001757073-25-000044.md) | [7.4 d](/filings/0001757073-25-000058.md) | [8.6 d](/filings/0001757073-26-000011.md) | [5.9](/filings/0001757073-26-000042.md) | [12.3 d](/filings/0001757073-26-000066.md) | [10.8 d](/filings/0001757073-25-000058.md) | [16.3 d](/filings/0001757073-26-000011.md) | [12.5](/filings/0001757073-26-000042.md) | [14.9 d](/filings/0001757073-26-000066.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-29) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | Q1 FY2025 (2025-03-28) | Q2 FY2025 (2025-06-27) | Q3 FY2025 (2025-09-26) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [177](/filings/0001757073-23-000071.md) | [177](/filings/0001757073-24-000039.md) | [176](/filings/0001757073-24-000066.md) | [175](/filings/0001757073-24-000078.md) | [173](/filings/0001757073-25-000028.md) | [172](/filings/0001757073-25-000044.md) | [173](/filings/0001757073-25-000058.md) | [174](/filings/0001757073-26-000042.md) | [170](/filings/0001757073-26-000066.md) | [166](/filings/0001757073-25-000058.md) | [166](/filings/0001757073-26-000042.md) | [164](/filings/0001757073-26-000066.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 160,617,709 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001757073-26-000066.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.